TY - JOUR
T1 - Transcatheter closure of patent foramen ovale in patients with cryptogenic stroke
AU - Butera, G.
AU - Bini, M. R.
AU - Chessa, M.
AU - Bedogni, F.
AU - Onofri, M.
AU - Carminati, M.
PY - 2001
Y1 - 2001
N2 - Background. About 50% of patients with cryptogenic stroke have a patent foramen ovale (PFO). The recurrence rate of paradoxical embolism is higher if a PFO is detected. Methods. Thirty-five patients with PFO and ≥1 thromboembolic event due to paradoxical embolism were included in the study (23 males, 12 females, mean age 47.8 ± 14 years, mean weight 75 ± 15 kg). Twenty-three patients had a transient ischemic attack whereas 12 experienced an ischemic stroke. Twenty-nine patients had one thromboembolic event, 4 patients had two thromboembolic events, and 2 patients had three thromboembolic events. The implantation procedure was performed, as previously reported, under general anesthesia, fluroscopic guidance and during transeophageal echocardiography. Results. The implantation procedure was successful in all patients. There were no complications related to the procedure. Four different devices were implanted (Amplatzer 3 patients; Cardioseal 12 patients; Starflex 12 patients, PFO Star 8 patients). The procedure time and fluoroscopic time were 50 ± 21.8 and 12.2 ± 8.3 min respectively. At transesophageal echocardiography performed after the procedure, 11 patients had a trivial shunt. None of the patients had a residual shunt at 1 month of follow-up. The mean follow-up was 12.3±8 months (median 11.0 months, range 3-37 months). In no patient did recurrence of a thromboembolic event occur during follow-up. Conclusions. Percutaneous PFO closure is a feasible and safe technique for the prevention of recurrent paradoxical embolism.
AB - Background. About 50% of patients with cryptogenic stroke have a patent foramen ovale (PFO). The recurrence rate of paradoxical embolism is higher if a PFO is detected. Methods. Thirty-five patients with PFO and ≥1 thromboembolic event due to paradoxical embolism were included in the study (23 males, 12 females, mean age 47.8 ± 14 years, mean weight 75 ± 15 kg). Twenty-three patients had a transient ischemic attack whereas 12 experienced an ischemic stroke. Twenty-nine patients had one thromboembolic event, 4 patients had two thromboembolic events, and 2 patients had three thromboembolic events. The implantation procedure was performed, as previously reported, under general anesthesia, fluroscopic guidance and during transeophageal echocardiography. Results. The implantation procedure was successful in all patients. There were no complications related to the procedure. Four different devices were implanted (Amplatzer 3 patients; Cardioseal 12 patients; Starflex 12 patients, PFO Star 8 patients). The procedure time and fluoroscopic time were 50 ± 21.8 and 12.2 ± 8.3 min respectively. At transesophageal echocardiography performed after the procedure, 11 patients had a trivial shunt. None of the patients had a residual shunt at 1 month of follow-up. The mean follow-up was 12.3±8 months (median 11.0 months, range 3-37 months). In no patient did recurrence of a thromboembolic event occur during follow-up. Conclusions. Percutaneous PFO closure is a feasible and safe technique for the prevention of recurrent paradoxical embolism.
KW - Catheterization
KW - Embolism
KW - Patent foramen ovale
UR - http://www.scopus.com/inward/record.url?scp=0035050996&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035050996&partnerID=8YFLogxK
M3 - Article
C2 - 11256538
AN - SCOPUS:0035050996
VL - 2
SP - 115
EP - 118
JO - Italian Heart Journal
JF - Italian Heart Journal
SN - 1129-471X
IS - 2
ER -